1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. HLA Typing for Transplant Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising incidence of bone marrow, organ, and blood transplant processes
5.1.1.2. Adoption of HLA typing in personalized medicine for reduced graft rejections
5.1.2. Restraints
5.1.2.1. Lack of reimbursement and inadequate insurance policies
5.1.3. Opportunities
5.1.3.1. Technological advancements in the field of transplant diagnostics and HLA-typing methods
5.1.3.2. Preference for immunosuppressive therapies to complement HLA typing
5.1.4. Challenges
5.1.4.1. Concerns regarding the inaccuracy of HLA typing
5.2. Market Segmentation Analysis
5.2.1. Technology: Adoption of molecular assay technologies due to their high specificity and reproducibility
5.2.2. Product & Service: Preference for software and services to facilitate data interpretation and managing laboratory workflow
5.2.3. Transplant Type: Increasing use of stem cell transplantation therapy for leukemia, lymphoma, myeloma, and immune system diseases
5.2.4. Application: Use of HLA typing in diagnostic applications for organ transplantation
5.2.5. End-User: High penetration in independent reference laboratories for high-throughput capabilities and scalability
5.3. Market Trend Analysis
5.3.1. Advanced Healthcare R&D and presence of established market vendors facilitate the expansion of HLA typing in Americas
5.3.2. Dynamically expanding HLA typing for transplant market in the APAC, with emphasis on advanced technology adoption for offering improved healthcare infrastructure for transplantation
5.3.3. Rising need for transplant procedures and government support for commercializing quality HLA typing to create a favorable market landscape in EMEA
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. HLA Typing for Transplant Market, by Product & Service
6.1. Introduction
6.2. Instruments
6.3. Reagents & Consumables
6.4. Software & Services
7. HLA Typing for Transplant Market, by Technology
7.1. Introduction
7.2. Molecular Assay Technologies
7.3.1. PCR-Based Molecular Assays
7.3.2.1. Real-Time PCR
7.3.2.2. Sequence-Specific Oligonucleotide-PCR
7.3.2.3. Sequence-Specific Primer-PCR
7.3.2. Sequencing-Based Molecular Assays
7.3.3.1. Next-Generation Sequencing
7.3.3.2. Sanger Sequencing
7.3. Non-Molecular Assay Technologies
8. HLA Typing for Transplant Market, by Transplant Type
8.1. Introduction
8.2. Organ Transplantation
8.3. Stem Cell Transplantation
8.4. Tissue Transplantation
9. HLA Typing for Transplant Market, by Application
9.1. Introduction
9.2. Diagnostic Applications
9.3.1. Antibody Screening
9.3.2. Chimerism Monitoring
9.3. Research Applications
10. HLA Typing for Transplant Market, by End-User
10.1. Introduction
10.2. Clinical Laboratories & Research Institution
10.3. Hospitals & Transplant Centers
10.4. Independent Reference Laboratories
11. Americas HLA Typing for Transplant Market
11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States
12. Asia-Pacific HLA Typing for Transplant Market
12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam
13. Europe, Middle East & Africa HLA Typing for Transplant Market
13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom
14. Competitive Landscape
14.1. FPNV Positioning Matrix
14.2. Market Share Analysis, By Key Player
14.3. Competitive Scenario Analysis, By Key Player
14.3.1. Merger & Acquisition
14.3.1.1. Eurobio Scientific acquires GenDx for USD 132.3 million
14.3.2. Agreement, Collaboration, & Partnership
14.3.2.1. JURA Bio Announces Partnership With Replay Product Company Syena to Advance T Cell Receptor NK Therapies in Cancer
14.3.2.2. Ossium Health and Be The Match Unveil Partnership to Increase Bone Marrow Transplant Accessibility and Treatment Efficiency
14.3.2.3. Tempus Announces Companion Diagnostic Collaboration with TScan Therapeutics
14.3.2.4. Be The Match BioTherapies, Atara Biotherapeutics Ink Multi-Year Partnership Extension
14.3.3. New Product Launch & Enhancement
14.3.3.1. GenDx launches NGS-Turbo: revolutionizing high-resolution HLA typing with Oxford Nanopore Technologies sequencing devices
14.3.3.2. Omixon Launches NanoTYPE MONO and MONOall RUO, a Singleplex Human Leukocyte Antigen Amplification kit compatible with Oxford Nanopore’s MinION Platform
14.3.3.3. Metropolis Healthcare unveils NextGen HLA test for organ transplantation
14.3.3.4. CD Genomics Longseq Division Unveils Human Leukocyte Antigen (HLA) Typing Service
14.3.3.5. FDA Grants De Novo Classification to HLA Typing Test for Use as a Companion Diagnostic with a T Cell Receptor Therapy for Metastatic or Unresectable Uveal Melanoma
14.3.4. Investment & Funding
14.3.4.1. BriaCell receives NCI grant for cancer platform development
14.3.4.2. Garuda Therapeutics Secures USD 62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform
15. Competitive Portfolio
15.1. Key Company Profiles
15.1.1. Agilent Technologies, Inc.
15.1.2. BAG Diagnostics GmbH
15.1.3. Becton, Dickinson, and Company
15.1.4. BGI Genomics Co.,Ltd.
15.1.5. Bio-Rad Laboratories, Inc.
15.1.6. Bio-Techne Corporation
15.1.7. CapitalBio Technology Co., Ltd.
15.1.8. CareDx, Inc.
15.1.9. CeGaT GmbH
15.1.10. Chugai Pharmaceutical Co., Ltd.
15.1.11. Creative Biolabs, Inc.
15.1.12. DiaSorin S.p.A.
15.1.13. Eurofins Scientific SE
15.1.14. F. Hoffman-La Roche AG
15.1.15. Fujirebio, Inc. by H.U. Group Holdings, Inc.
15.1.16. Garuda Therapeutics
15.1.17. GenDx by Eurobio Scientific Group
15.1.18. HEALIOS K.K.
15.1.19. Hologic, Inc.
15.1.20. Illumina, Inc.
15.1.21. Immatics N.V.
15.1.22. Immucor, Inc. by Werfen, S.A.
15.1.23. ImmunOs Therapeutics AG
15.1.24. Invectys Inc.
15.1.25. Laboratory Corporation of America Holdings
15.1.26. Lonza Group Ltd.
15.1.27. Merck KGaA
15.1.28. NeoGenomics Laboratories, Inc.
15.1.29. OraSure Technologies, Inc.
15.1.30. Oxford Nanopore Technologies PLC
15.1.31. Pure MHC, LLC
15.1.32. Pure Protein, LLC
15.1.33. QIAGEN N.V.
15.1.34. STEMCELL Technologies Inc.
15.1.35. T-Cure Bioscience Inc.
15.1.36. Takara Bio Inc.
15.1.37. TBG Diagnostics Ltd.
15.1.38. TCR² Therapeutics by Adaptimmune Therapeutics PLC
15.1.39. Thermo Fisher Scientific, Inc.
15.2. Key Product Portfolio
16. Appendix
16.1. Discussion Guide
16.2. License & Pricing